Colorectal cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• KRAS 57
• PD-1 108
• BRAF 36
• EGFR 32
• PD-L1 26
• PI3K 2
• STAT3 0
• CTNNB1 1
• AKT 0
• RAS 31
• HER2 38
• mTOR 1
• MAPK 1
• VEGF 14
• ERK 0
• STING 0
• NRF2 0
• PPAR 0
• CTLA-4 16
• HIF-1 0
• COX-2 5
• JNK 0
• AMPK 0
• MYC 0
• PTEN 1
• YAP 0
• GPX4 0
• NRAS 8
• IL-6 0
• JAK 0
• MET 7
• PARP 1
• CXCR4 0
• TNF 0
• NLRP3 0
• BCL-2 0
• HSP90 0
• PIK3CA 2
• GLP-1 1
• HDAC 2
• METTL3 0
• CDK4/6 2
• MEK 1
• CD47 1
• FGFR 0
• BRCA1 1
• NTRK 1
• B7-H3 5
• EZH2 0
• FAK 1
• HMGB1 0
• TROP2 4
• MUC1 2
• ATM 2
• IDO1 1
• IL-1 0
• PCSK9 3
• PINK1 0
• SHP2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 54+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Updated 23 Oct 2026

  “Company's strategic decision”Registry text, quoted unchanged. Source

• Terminated

  Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  NCT05358249· Novartis Pharmaceuticals· Updated 21 Oct 2026

  “Business reasons and not based on any safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

  NCT06039384· Incyte Corporation· Updated 8 Sept 2026

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”Registry text, quoted unchanged. Source

• Withdrawn

  IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

  NCT06487377· Shanghai Pudong Hospital· Updated 2 Sept 2026

  “Study was stopped Sponsor discretion. No patients were dosed.”Registry text, quoted unchanged. Source

• Terminated

  A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

  NCT05497336· Innovent Biologics (Suzhou) Co. Ltd.· Updated 19 Aug 2026

  “company development strategy adjustment”Registry text, quoted unchanged. Source

• Terminated

  A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  NCT06585488· BeOne Medicines· Updated 8 Jul 2026

  “The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

  NCT06704724· Pfizer· Updated 22 May 2026

  “The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”Registry text, quoted unchanged. Source

• Suspended

  A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

  NCT05200442· University of Chicago· Updated 8 May 2026

  “enrollment goal met pending determination of evaluable subjects”Registry text, quoted unchanged. Source

• Terminated

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· Inspirna, Inc.· Updated 20 Feb 2026

  “At the time of the primary analysis, results did not meet the primary endpoint”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

  NCT05578092· Mirati Therapeutics Inc.· Updated 19 Feb 2026

  “business objectives have changed”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Merck Sharp & Dohme LLC· Source

• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

  NCT07659795· Verastem, Inc.· Source

• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

  NCT03190941· National Cancer Institute (NCI)· Source

• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

  NCT07094204· Astellas Pharma Inc· Source

• MRD Monitoring in Colorectal Cancer Using ctDNA

  NCT07895459· Masaryk Memorial Cancer Institute· Source

• A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

  NCT06364696· Astellas Pharma Inc· Source

• Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

  NCT07468071· Novartis Pharmaceuticals· Source

• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  NCT05358249· Novartis Pharmaceuticals· Source

• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

  NCT04699188· Novartis Pharmaceuticals· Source

• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

  NCT06253520· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 133
• Organoids 108
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 34
• Gene Expression Profiling 338
• Sequence Analysis, RNA 29
• Whole Genome Sequencing 22
• Exome Sequencing 26
• Proteomics 107
• Metabolomics 92
• Mass Spectrometry 42
• Flow Cytometry 113
• Immunohistochemistry 208
• Liquid Biopsy 36
• Circulating Tumor DNA 119
• Xenograft Model Antitumor Assays 432
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 196
• Machine Learning 211
• Deep Learning 142
• Cohort Studies 317
• Genome-Wide Association Study 65

• Vascular Proliferation Index Via a Single-Cell Analysis Is a Superior Prognostic Biomarker to Microvessel Density in Stage II/III Colorectal Cancer.

  Anticancer Res, Oct 2026

• A Multimodal Framework to Assess Patient-Derived Colon Tumor Organoid-Immune Cell Co-cultures.

  J Vis Exp, Sept 2026

• Spectral cytometry-based immune profiling coupled with machine learning identifies circulating Th1-like cells as a blood biomarker for advanced colorectal adenomas.

  Eur J Cancer, Aug 2026

• Comparison of Tissue Preparations to Identify and Phenotype T Cells in Human Colorectal Tumor Tissue.

  Cytometry A, Jun 2026

• Cytometry by Time-of-Flight for Profiling Therapeutic Response in Colorectal Cancer: Strengths, Limitations, and Translational Challenges.

  Anticancer Res, May 2026

• Perforin and Granulysin-Mediated Cytotoxicity in Colorectal Cancer Patients.

  Medicina (Kaunas), Apr 2026

• Bridging Target Recognition with Direct Molecular Counting: A DNA Framework Converter-Mediated nFCM Assay Platform for Quantifying Diverse Biochemical Analytes.

  Anal Chem, Mar 2026

• Characterization of Lymphocyte Subsets in Peripheral Blood of Patients with Colorectal Cancer.

  J Gastrointest Cancer, Feb 2026

• Peripheral blood immune cell subsets as non-invasive biomarkers of colorectal cancer stage, laterality, metastasis and survival.

  Cell Oncol (Dordr), Feb 2026

• Single-cell mass cytometry reveals distinct immune signatures in colorectal cancer.

  Anal Methods, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.